2.80
price down icon4.44%   -0.13
pre-market  Vorhandelsmarkt:  2.81   0.01   +0.36%
loading

Savara Inc Aktie (SVRA) Neueste Nachrichten

pulisher
Jan 18, 2025

Savara Inc Updates Corporate Presentation in Latest SEC Filing - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

Savara (NASDAQ:SVRA) Stock Price Down 5.3%Here's What Happened - MarketBeat

Jan 17, 2025
pulisher
Jan 16, 2025

Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN

Jan 16, 2025
pulisher
Jan 15, 2025

Savara Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference - MSN

Jan 15, 2025
pulisher
Jan 15, 2025

Savara (NASDAQ:SVRA) Shares Up 8.1%Should You Buy? - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Barclays PLC Buys 158,244 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Jan 15, 2025
pulisher
Jan 13, 2025

Savara Highlights MOLBREEVI’s Potential in Rare Disease Market - TipRanks

Jan 13, 2025
pulisher
Jan 11, 2025

Institutional investors may adopt severe steps after Savara Inc.'s (NASDAQ:SVRA) latest 11% drop adds to a year losses - Simply Wall St

Jan 11, 2025
pulisher
Jan 11, 2025

Savara Inc (NASDAQ:SVRA) Shares Sold by Jane Street Group LLC - Defense World

Jan 11, 2025
pulisher
Jan 11, 2025

SVRA Stock Touches 52-Week Low at $2.81 Amid Market Challenges By Investing.com - Investing.com South Africa

Jan 11, 2025
pulisher
Jan 10, 2025

SVRA Stock Touches 52-Week Low at $2.81 Amid Market Challenges - Investing.com Australia

Jan 10, 2025
pulisher
Jan 09, 2025

Savara Inc. Grants Inducement Awards to New Employees - MSN

Jan 09, 2025
pulisher
Jan 08, 2025

Principal Financial Group Inc. Sells 7,607 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Jan 08, 2025
pulisher
Jan 04, 2025

Savara Inc (NASDAQ:SVRA) Receives $9.86 Average Price Target from Brokerages - Defense World

Jan 04, 2025
pulisher
Jan 01, 2025

Savara Inc (NASDAQ:SVRA) Receives $9.86 Consensus Target Price from Analysts - MarketBeat

Jan 01, 2025
pulisher
Jan 01, 2025

Geode Capital Management LLC Raises Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Jan 01, 2025
pulisher
Jan 01, 2025

Geode Capital Management LLC Buys 264,825 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat

Jan 01, 2025
pulisher
Dec 31, 2024

Barclays PLC Increases Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World

Dec 31, 2024
pulisher
Dec 29, 2024

Who Really Pulls the Strings at Savara? Discover the Power Players! - Jomfruland.net

Dec 29, 2024
pulisher
Dec 29, 2024

Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance

Dec 29, 2024
pulisher
Dec 28, 2024

Savara Begins FDA Submission for Rare Lung Disease Treatment - MSN

Dec 28, 2024
pulisher
Dec 25, 2024

State Street Corp Acquires 560,242 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat

Dec 25, 2024
pulisher
Dec 25, 2024

State Street Corp Purchases 560,242 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Dec 25, 2024
pulisher
Dec 23, 2024

Savara Strengthens Team with Strategic Equity Incentives: 200,000 Shares Awarded to New Hires - StockTitan

Dec 23, 2024
pulisher
Dec 21, 2024

Savara (NASDAQ:SVRA) Earns “Market Outperform” Rating from JMP Securities - Defense World

Dec 21, 2024
pulisher
Dec 21, 2024

Wells Fargo Initiates Coverage of Savara (SVRA) with Overweight Recommendation - MSN

Dec 21, 2024
pulisher
Dec 21, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 6,141 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Dec 21, 2024
pulisher
Dec 20, 2024

Savara: Rolling BLA Submission Of MOLBREEVI Generates Catalysts To Track (NASDAQ:SVRA) - Seeking Alpha

Dec 20, 2024
pulisher
Dec 20, 2024

Savara (NASDAQ:SVRA) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Savara's SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Australia

Dec 20, 2024
pulisher
Dec 19, 2024

Savara's SWOT analysis: rare disease biotech stock poised for growth - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

Savara (NASDAQ:SVRA) Trading 5.6% HigherTime to Buy? - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

BNP Paribas Financial Markets Purchases 18,534 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Dec 19, 2024
pulisher
Dec 19, 2024

JMP Securities Reaffirms "Market Outperform" Rating for Savara (NASDAQ:SVRA) - MarketBeat

Dec 19, 2024
pulisher
Dec 18, 2024

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire

Dec 18, 2024
pulisher
Dec 17, 2024

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace

Dec 17, 2024
pulisher
Dec 17, 2024

Savara's CFO David Lowrance sells $83,277 in stock By Investing.com - Investing.com South Africa

Dec 17, 2024
pulisher
Dec 17, 2024

The Manufacturers Life Insurance Company Acquires 3,706 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Dec 17, 2024
pulisher
Dec 17, 2024

Savara director Hawkins sells $26,568 in stock By Investing.com - Investing.com Australia

Dec 17, 2024
pulisher
Dec 17, 2024

Savara director Hawkins sells $26,568 in stock - Investing.com India

Dec 17, 2024
pulisher
Dec 17, 2024

Savara CEO Matthew Pauls sells $180,828 in stock - Investing.com India

Dec 17, 2024
pulisher
Dec 16, 2024

Savara's SWOT analysis: molgramostim's promise buoys stock amid challenges - Investing.com

Dec 16, 2024
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
Kapitalisierung:     |  Volumen (24h):